Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Geriatrics
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Geriatrics
    Coronary Arterial Calcium Scans Help Detect Overall Death Risk in the Elderly - (DGNews)
    Long-Term Use of Alendronate Puts Some Patients at Risk for Fracture - (DGNews)
    Ultrasound Exam May Predict Risk for Fractures From Osteoporosis in Elderly Women - (DGNews)
    Subtle Nervous System Abnormalities Predict Risk of Death in Elderly - (DGNews)
    Incident Dementia Reduced by Antihypertensive Therapy in Elderly Hypertensive Patients: Presented at ESH - (DGDispatch)

    News archive

     Recent webcasts/CME - Geriatrics

    Webcasts/CME archive

     Recent cases - Geriatrics
      Torsion of Vermiform Appendix with Fecalith: A Case Report
      Solitary Skull Metastasis as Initial Manifestation of Hepatocellular Carcinoma
      FDG PET-CT Demonstration of Metastatic Neuroendocrine Tumor of Prostate
      Kaposi's Sarcoma of the Hand Mimicking Squamous Cell Carcinoma in a Woman with No Evidence of HIV Infection: A Case Report
      Coexistence of Primary Adenocarcinoma of the Lung and Tsukamurella Pneumonia: A Case Report and Review of the Literature

      Cases archive
        




      my personal edition > geriatrics > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Switch From Donepezil Tablets to Rivastigmine Transdermal Patch Safe in Alzheimer's Disease: Presented at AGS

      By Crina Frincu-Mallos, PhD

      WASHINGTON, DC -- May 12, 2008 -- Switching medications is an option for patients who do not adhere to prescribed treatment due to tolerability issues, lack of initial efficacy, or loss of efficacy when the drug is taken for a long time.

      For patients with Alzheimer's disease who are noncompliant with their treatment regimen, treatment with donepezil tablets alone or in combination with memantine can be switched safely to the rivastigmine transdermal patch without a washout period.

      Lead author Gus Alva, MD, Medical Director, ATP Clinical Research, Costa Mesa, California, and colleagues reported their findings here in a poster presentation at the 2008 Annual Scientific Meeting of the American Geriatrics Society (AGS).

      "The transdermal patch of rivastigmine is as efficacious as the highest dose of rivastigmine capsules [6 mg, given twice daily], while its use results in approximately one third the gastrointestinal toxicities observed with the capsules," said Dr. Alva.

      As part of the open-label, randomised, multicentre, parallel-group Switch From Aricept to Patch (SWAP) study, Dr. Alva and colleagues enrolled 262 patients with Alzheimer's disease, mean age 77 years. Men and women were enrolled in a 2:3 ratio. The mean duration of dementia for patients on trial was 4 years.

      The researchers aimed to assess the tolerability and safety of switching from donepezil tablets, given as a single-agent or in combination with memantine, to rivastigmine transdermal patch.

      The study included a 28-day screening phase, after which the patients were randomised to a 5-week core phase consisting of an immediate-switch arm in 131 patients and a delayed-switch arm in 130 patients. One patient in the delayed-switch group chose to discontinue treatment during the baseline visit.

      Patients in the immediate-switch arm replaced the donepezil tablets 5 to 10 mg daily with the rivastigmine transdermal patch 4.6 mg/24 hours, while patients on the delayed-switch arm replaced the medications after a 7-day washout period.

      Patients receiving memantine in combination with donepezil at day 1 were allowed to continue with the same dose of memantine throughout the study; they represented fewer than half of the total number of patients in the study.

      "The rivastigmine transdermal patch was generally well tolerated by patients in both treatment groups," said Dr. Alva, adding that "a total of 36 [27.5%] patients in the immediate-switch group and 45 [34.6%] patients in the delayed-switch group experienced at least 1 adverse event (AE) during the 5-week core phase."

      However, 2 patients in the immediate-switch group experienced serious AEs -- lethargy and bradycardia, respectively; both AEs were considered by the investigators to be related to the study medications.

      The most frequent AEs in the immediate-switch group were nausea (n = 5); decreased appetite (n = 4); bradycardia, hallucination, agitation (n = 3); and somnolence (n = 2).

      The most frequent AEs in the delayed-switch group were constipation (n = 6), application-site reaction (n = 5), somnolence (n = 4), agitation (n = 3), and nausea (n = 1).

      "With the exception of 1 case of moderate dermatitis, these AEs were all mild in severity," said Dr. Alva, and mean values for heart rate, supine pulse rate, and systolic and diastolic blood pressure were small and not clinically meaningful in both switch paradigm groups.

      Eleven patients in the immediate-switch arm and 10 patients in the delayed-switch arm discontinued treatment, mostly due to adverse events, the researchers noted.

      In terms of efficacy, patients in the immediate-switch group had a mean score of 3.9 on the Clinical Global Impression of Change scale, compared with 4.0 in the other group, and the difference was neither statistically nor clinically meaningful, noted Dr. Alva.

      "The difference in AEs reported between treatment groups suggests that there may be a subset of patients, with low body weight or with cardiac conduction problems, for whom a delayed switch should be considered," concluded Dr. Alva.

      Funding for this study was provided by Novartis Pharmaceuticals Corporation.


      [Presentation title: SWAP: The Safety and Tolerability of Switching From Donepezil Tablets to Rivastigmine Transdermal Patch in Alzheimer's Disease. Abstract B37]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send